GLP-1 receptor agonists are now among the fastest-growing therapeutic classes, with semaglutide supporting an expanding range of clinical programs. Our lab offers a proprietary semaglutide assay designed for accurate, reproducible bioanalysis across development stages.



Accurate pharmacokinetic profiling of monoclonal antibodies via LC-MS/MS bioanalysis is critical for dose selection and safety assessment. Our proprietary IgG 1 and IgG 4 assays deliver robust quantification across the full PK curve, supporting accurate exposure assessment.